Source Fact: Financial Supervisory Service DART / 2024-07-02
Disclosure Type: Major Management Matters Related to Investment Judgment (Amendment)
💡 3-Second Summary
Samsung Biologics has amended its Letter of Intent (LOI) for a biopharmaceutical contract manufacturing agreement worth approximately KRW 147.3B, extending the client confidentiality (withholding) deadline from July 30, 2024, to December 31, 2030, per the client’s request.
📊 1. [Summary of Core Disclosure & Key Figures]
- Amended Original Disclosure: Major Management Matters Related to Investment Judgment initially submitted on June 5, 2023
- Contract Name: Conclusion of Letter of Intent (LOI) for Biopharmaceutical Contract Manufacturing
- Contract Amount: KRW 147,284,499,200 (Fixed amount: USD 112,534,000)
- Applied FX Rate: Fixed at KRW 1,308.80 per USD (The standard proxy rate on the initial disclosure date of June 5, 2023)
- Ratio to Revenue: 4.91% relative to the annual revenue baseline at the time of initial disclosure (KRW 3.00T)
- Counterparty: A pharmaceutical company located in the United States (Identity remaining confidential due to trade secrecy)
- Contract Period: From the LOI execution date (June 3 days, 2023) until the execution of the definitive formal contract
- Changes in Disclosure Withholding Expiration:
- Pre-amendment: July 30, 2024
- Post-amendment: December 31, 2030 (Extended by approximately 6 years and 5 months)
- Note: The designated contract value remains legally binding between both parties. Upon the execution of the definitive formal contract in the future, finalized updates will be re-disclosed.
📈 2. [Expert Insight: Implications for Investors]
- Contract Validity Maintained with Extended Secrecy Strategy: This amendment involves no alterations to the total contract value, solely shifting the disclosure withholding expiration date at the client’s request. It signals that the LOI executed in 2023 remains fully legally effective, though both parties have agreed to maintain strict security regarding the client’s identity over a prolonged period.
- Limited Immediate Financial Volatility: Because this is an administrative timeline shift for confidentiality rather than a cancellation or value reduction, the immediate impact on the company’s current financial Fundamental remains highly limited.
- Investor Consideration: With the confidentiality deadline deferred to late 2030, the specific identity and profile of the U.S. counterparty are likely to remain undisclosed for an extended timeline before or even after the definitive contract transition. Market participants must navigate this prolonged structural information asymmetry during the validation process from an LOI to a formal agreement.
📝 Editor’s Comment (by K-STOCK Editor)
The confidentiality window for the U.S. CMO Letter of Intent (LOI), active since mid-2023, has been significantly deferred from July 2024 all the way to December 2030. While this long-term extension does not impact the recorded order book value or indicate any structural flaw in Fundamental, it means that the client’s identity will remain masked much longer than initially expected. In the commercial biopharma landscape, shielding a partner’s profile for multiple years due to competitive research strategies or market rollouts is a recognized practice. Since the legally binding KRW 147.3 billion backlog remains fully intact, shareholders should patiently look past the lack of immediate corporate disclosure and track how this framework ultimately shapes the definitive contract conversion notice.
📢 Disclaimer & Source Information
Source: This content was structured and newly generated based on official data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).
Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial liabilities rest entirely with the investor.
Contact: For compliance-related inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
